1
|
Xiao Z, Yang MG, Liu C, Sherwood T, Gilmore JL, Lin J, Li P, Wu DR, Tokarski J, Li S, Cheng L, Xie C, Fan J, Dierks E, Strnad J, Cvijic ME, Khan J, Ruzanov M, Galella M, Khandelwal P, Dyckman AJ, Mathur A, Lombardo LJ, Macor JE, Carter PH, Aranibar N, Burke JR, Weinstein DS. Structure-activity relationship study of central pyridine-derived TYK2 JH2 inhibitors: Optimization of the PK profile through C4' and C6 variations. Bioorg Med Chem Lett 2023; 91:129373. [PMID: 37315697 DOI: 10.1016/j.bmcl.2023.129373] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Revised: 05/22/2023] [Accepted: 06/07/2023] [Indexed: 06/16/2023]
Abstract
Efforts directed at improving potency and preparing structurally different TYK2 JH2 inhibitors from the first generation of compounds such as 1a led to the SAR study of new central pyridyl based analogs 2-4. The current SAR study resulted in the identification of 4h as a potent and selective TYK2 JH2 inhibitor with distinct structural differences from 1a. In this manuscript, the in vitro and in vivo profiles of 4h are described. The hWB IC50 of 4h was shown as 41 nM with 94% bioavailability in the mouse PK study.
Collapse
Affiliation(s)
- Zili Xiao
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States.
| | - Michael G Yang
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Chunjian Liu
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Trevor Sherwood
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John L Gilmore
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - James Lin
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Peng Li
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Dauh-Rurng Wu
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John Tokarski
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Sha Li
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Lihong Cheng
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Chunshan Xie
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Jingsong Fan
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Elizabeth Dierks
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Joann Strnad
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Mary Ellen Cvijic
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Javed Khan
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Max Ruzanov
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Michael Galella
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Purnima Khandelwal
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Alaric J Dyckman
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Arvind Mathur
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Louis J Lombardo
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - John E Macor
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Percy H Carter
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - Nelly Aranibar
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - James R Burke
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| | - David S Weinstein
- Research and Development, Bristol-Myers Squibb Company, Princeton, NJ 08543-4000, United States
| |
Collapse
|
2
|
Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X, Pawluczyk J, Yip S, Luk E, Raghavan N, Swanson J, Smalley J, Murtaza A, Yang Z, Augustine-Rauch K, Lombardo LJ, Borzilleri R. Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor. J Med Chem 2021; 64:15787-15798. [PMID: 34704759 DOI: 10.1021/acs.jmedchem.0c02043] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Inhibition of TGFβ signaling in concert with a checkpoint blockade has been shown to provide improved and durable antitumor immune response in mouse models. However, on-target adverse cardiovascular effects have limited the clinical use of TGFβ receptor (TGFβR) inhibitors in cancer therapy. To restrict the activity of TGFβR inhibitors to tumor tissues and thereby widen the therapeutic index, a series of tumor-activated prodrugs of a selective small molecule TGFβR1 inhibitor 1 were prepared by appending 1 to a serine protease substrate and a half-life extension fatty acid carbon chain. The prodrugs were shown to be selectively metabolized in tumor tissues relative to the heart and blood and demonstrated a prolonged favorable increase in the tumor-to-heart ratio of the active drug in tissue distribution studies. Once-weekly administration of the most tissue-selective compound 10 provided anti-tumor efficacy comparable to the parent compound and reduced systemic exposure of the active drug.
Collapse
Affiliation(s)
- Yong Zhang
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Karen E Parrish
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - David R Tortolani
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Michael A Poss
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Audris Huang
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Honghe Wan
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Ashok V Purandare
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Andrew F Donnell
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - James Kempson
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Xiaoping Hou
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Joseph Pawluczyk
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Shiuhang Yip
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Emily Luk
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Nimmi Raghavan
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Jesse Swanson
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - James Smalley
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Anwar Murtaza
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Zheng Yang
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Karen Augustine-Rauch
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Louis J Lombardo
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| | - Robert Borzilleri
- Bristol Myers Squibb, Research and Early Development, P.O. Box 4000, Princeton, New Jersey 08544, United States
| |
Collapse
|
3
|
Liu C, Lin J, Langevine C, Smith D, Li J, Tokarski JS, Khan J, Ruzanov M, Strnad J, Zupa-Fernandez A, Cheng L, Gillooly KM, Shuster D, Zhang Y, Thankappan A, McIntyre KW, Chaudhry C, Elzinga PA, Chiney M, Chimalakonda A, Lombardo LJ, Macor JE, Carter PH, Burke JR, Weinstein DS. Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2. J Med Chem 2020; 64:677-694. [PMID: 33370104 DOI: 10.1021/acs.jmedchem.0c01698] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
A search for structurally diversified Tyk2 JH2 ligands from 6 (BMS-986165), a pyridazine carboxamide-derived Tyk2 JH2 ligand as a clinical Tyk2 inhibitor currently in late development for the treatment of psoriasis, began with a survey of six-membered heteroaryl groups in place of the N-methyl triazolyl moiety in 6. The X-ray co-crystal structure of an early lead (12) revealed a potential new binding pocket. Exploration of the new pocket resulted in two frontrunners for a clinical candidate. The potential hydrogen bonding interaction with Thr599 in the pocket was achieved with a tertiary amide moiety, confirmed by the X-ray co-crystal structure of 29. When the diversity search was extended to nicotinamides, a single fluorine atom addition was found to significantly enhance the permeability, which directly led to the discovery of 7 (BMS-986202) as a clinical Tyk2 inhibitor that binds to Tyk2 JH2. The preclinical studies of 7, including efficacy studies in mouse models of IL-23-driven acanthosis, anti-CD40-induced colitis, and spontaneous lupus, will also be presented.
Collapse
Affiliation(s)
- Chunjian Liu
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James Lin
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Charles Langevine
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Daniel Smith
- Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Jianqing Li
- Department of Discovery Synthesis, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - John S Tokarski
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Javed Khan
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Max Ruzanov
- Molecular Structure and Design, Molecular Discovery Technologies, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Joann Strnad
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Adriana Zupa-Fernandez
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Lihong Cheng
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kathleen M Gillooly
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - David Shuster
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Yifan Zhang
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anil Thankappan
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Kim W McIntyre
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Charu Chaudhry
- Leads Discovery and Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Paul A Elzinga
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Manoj Chiney
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Anjaneya Chimalakonda
- Metabolism and Pharmacokinetic Department, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Louis J Lombardo
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - John E Macor
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - Percy H Carter
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - James R Burke
- Immunosciences Discovery Biology, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| | - David S Weinstein
- Immunosciences Discovery Chemistry, Bristol-Myers Squibb Research & Development, P.O. Box 4000, Princeton, New Jersey 08543, United States
| |
Collapse
|
4
|
Liu C, Lin J, Moslin R, Tokarski JS, Muckelbauer J, Chang C, Tredup J, Xie D, Park H, Li P, Wu DR, Strnad J, Zupa-Fernandez A, Cheng L, Chaudhry C, Chen J, Chen C, Sun H, Elzinga P, D’arienzo C, Gillooly K, Taylor TL, McIntyre KW, Salter-Cid L, Lombardo LJ, Carter PH, Aranibar N, Burke JR, Weinstein DS. Identification of Imidazo[1,2- b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors. ACS Med Chem Lett 2019; 10:383-388. [PMID: 30891145 DOI: 10.1021/acsmedchemlett.9b00035] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2019] [Accepted: 02/21/2019] [Indexed: 01/12/2023] Open
Abstract
In sharp contrast to a previously reported series of 6-anilino imidazopyridazine based Tyk2 JH2 ligands, 6-((2-oxo-N1-substituted-1,2-dihydropyridin-3-yl)amino)imidazo[1,2-b]pyridazine analogs were found to display dramatically improved metabolic stability. The N1-substituent on 2-oxo-1,2-dihydropyridine ring can be a variety of alkyl, aryl, and heteroaryl groups, but among them, 2-pyridyl provided much enhanced Caco-2 permeability, attributed to its ability to form intramolecular hydrogen bonds. Further structure-activity relationship studies at the C3 position led to the identification of highly potent and selective Tyk2 JH2 inhibitor 6, which proved to be highly effective in inhibiting IFNγ production in a rat pharmacodynamics model and fully efficacious in a rat adjuvant arthritis model.
Collapse
Affiliation(s)
- Chunjian Liu
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - James Lin
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Ryan Moslin
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - John S. Tokarski
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jodi Muckelbauer
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - ChiehYing Chang
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jeffrey Tredup
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Dianlin Xie
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Hyunsoo Park
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Peng Li
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Dauh-Rurng Wu
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Joann Strnad
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Adriana Zupa-Fernandez
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Lihong Cheng
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Charu Chaudhry
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Jing Chen
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Cliff Chen
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Huadong Sun
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Paul Elzinga
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Celia D’arienzo
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Kathleen Gillooly
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Tracy L. Taylor
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Kim W. McIntyre
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Luisa Salter-Cid
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Louis J. Lombardo
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Percy H. Carter
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - Nelly Aranibar
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - James R. Burke
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| | - David S. Weinstein
- Research & Development, Bristol-Myers Squibb, P.O. Box 5400, Princeton, New Jersey 08543, United States
| |
Collapse
|
5
|
Marcoux D, Xiao HY, Murali Dhar TG, Xie J, Lehman-McKeeman LD, Wu DR, Dabros M, Yang X, Taylor TL, Zhou XD, Heimrich EM, Thomas R, McIntyre KW, Shi H, Levesque PC, Sun H, Yang Z, Marino AM, Cornelius G, D'Arienzo CJ, Gupta A, Pragalathan B, Rampulla R, Mathur A, Shen DR, Cvijic ME, Salter-Cid L, Lombardo LJ, Carter PH, Dyckman AJ. Identification of potent tricyclic prodrug S1P 1 receptor modulators. Medchemcomm 2016; 8:725-729. [PMID: 30108791 DOI: 10.1039/c6md00539j] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/26/2016] [Accepted: 11/21/2016] [Indexed: 12/31/2022]
Abstract
Recently, our research group reported the identification of prodrug amino-alcohol 2 as a potent and efficacious S1P1 receptor modulator. This molecule is differentiated preclinically over the marketed drug fingolimod (Gilenya 1), whose active phosphate metabolite is an S1P1 full agonist, in terms of pulmonary and cardiovascular safety. S1P1 partial agonist 2, however, has a long half-life in rodents and was projected to have a long half-life in humans. The purpose of this communication is to disclose highly potent partial agonists of S1P1 with shorter half-lives relative to the clinical compound 2. PK/PD relationships as well as their preclinical pulmonary and cardiovascular safety assessment are discussed.
Collapse
Affiliation(s)
- David Marcoux
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Hai-Yun Xiao
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - T G Murali Dhar
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Jenny Xie
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Lois D Lehman-McKeeman
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Marta Dabros
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Xiaoxia Yang
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Tracy L Taylor
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Xia D Zhou
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Elizabeth M Heimrich
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Rochelle Thomas
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Kim W McIntyre
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Hong Shi
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Paul C Levesque
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Huadong Sun
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Zheng Yang
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Anthony M Marino
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Georgia Cornelius
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Celia J D'Arienzo
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | | | | | - Richard Rampulla
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Arvind Mathur
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Ding Ren Shen
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Mary Ellen Cvijic
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Luisa Salter-Cid
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Louis J Lombardo
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Percy H Carter
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| | - Alaric J Dyckman
- Bristol-Myers Squibb Company , Princeton , New Jersey 08543-4000 , USA . ; ; Tel: +1 609 252 3980
| |
Collapse
|
6
|
Hart AC, Schroeder GM, Wan H, Grebinski J, Inghrim J, Kempson J, Guo J, Pitts WJ, Tokarski JS, Sack JS, Khan JA, Lippy J, Lorenzi MV, You D, McDevitt T, Vuppugalla R, Zhang Y, Lombardo LJ, Trainor GL, Purandare AV. Structure-Based Design of Selective Janus Kinase 2 Imidazo[4,5-d]pyrrolo[2,3-b]pyridine Inhibitors. ACS Med Chem Lett 2015; 6:845-9. [PMID: 26288682 DOI: 10.1021/acsmedchemlett.5b00225] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 07/10/2015] [Indexed: 12/12/2022] Open
Abstract
Early hit to lead work on a pyrrolopyridine chemotype provided access to compounds with biochemical and cellular potency against Janus kinase 2 (JAK2). Structure-based drug design along the extended hinge region of JAK2 led to the identification of an important H-bond interaction with the side chain of Tyr 931, which improved JAK family selectivity. The 4,5-dimethyl thiazole analogue 18 demonstrated high levels of JAK family selectivity and was identified as a promising lead for the program.
Collapse
Affiliation(s)
- Amy C. Hart
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Gretchen M. Schroeder
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Honghe Wan
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - James Grebinski
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Jennifer Inghrim
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - James Kempson
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Junqing Guo
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - William J. Pitts
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - John S. Tokarski
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - John S. Sack
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Javed A. Khan
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Jonathan Lippy
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Matthew V. Lorenzi
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Dan You
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Theresa McDevitt
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Ragini Vuppugalla
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Yueping Zhang
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Louis J. Lombardo
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - George L. Trainor
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| | - Ashok V. Purandare
- Bristol-Myers Squibb Research & Development, Princeton, New Jersey 08543, United States
| |
Collapse
|
7
|
Wan H, Schroeder GM, Hart AC, Inghrim J, Grebinski J, Tokarski JS, Lorenzi MV, You D, Mcdevitt T, Penhallow B, Vuppugalla R, Zhang Y, Gu X, Iyer R, Lombardo LJ, Trainor GL, Ruepp S, Lippy J, Blat Y, Sack JS, Khan JA, Stefanski K, Sleczka B, Mathur A, Sun JH, Wong MK, Wu DR, Li P, Gupta A, Arunachalam PN, Pragalathan B, Narayanan S, K.C. N, Kuppusamy P, Purandare AV. Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative Neoplasms. ACS Med Chem Lett 2015; 6:850-5. [PMID: 26288683 DOI: 10.1021/acsmedchemlett.5b00226] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2015] [Accepted: 07/12/2015] [Indexed: 12/16/2022] Open
Abstract
JAK2 kinase inhibitors are a promising new class of agents for the treatment of myeloproliferative neoplasms and have potential for the treatment of other diseases possessing a deregulated JAK2-STAT pathway. X-ray structure and ADME guided refinement of C-4 heterocycles to address metabolic liability present in dialkylthiazole 1 led to the discovery of a clinical candidate, BMS-911543 (11), with excellent kinome selectivity, in vivo PD activity, and safety profile.
Collapse
Affiliation(s)
- Honghe Wan
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Gretchen M. Schroeder
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Amy C. Hart
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Jennifer Inghrim
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - James Grebinski
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - John S. Tokarski
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Matthew V. Lorenzi
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Dan You
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Theresa Mcdevitt
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Becky Penhallow
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Ragini Vuppugalla
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Yueping Zhang
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Xiaomei Gu
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Ramaswamy Iyer
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Louis J. Lombardo
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - George L. Trainor
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Stefan Ruepp
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Jonathan Lippy
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Yuval Blat
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - John S. Sack
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Javed A. Khan
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Kevin Stefanski
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Bogdan Sleczka
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Arvind Mathur
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Jung-Hui Sun
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Michael K. Wong
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Peng Li
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Anuradha Gupta
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - P. N. Arunachalam
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Bala Pragalathan
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Sankara Narayanan
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Nanjundaswamy K.C.
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Prakasam Kuppusamy
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| | - Ashok V. Purandare
- Bristol-Myers Squibb R&D, US Route 206 and Province Line Road, Princeton, New Jersey 08543-4000, United States
| |
Collapse
|
8
|
Gavai AV, Quesnelle C, Norris D, Han WC, Gill P, Shan W, Balog A, Chen K, Tebben A, Rampulla R, Wu DR, Zhang Y, Mathur A, White R, Rose A, Wang H, Yang Z, Ranasinghe A, D’Arienzo C, Guarino V, Xiao L, Su C, Everlof G, Arora V, Shen DR, Cvijic ME, Menard K, Wen ML, Meredith J, Trainor G, Lombardo LJ, Olson R, Baran PS, Hunt JT, Vite GD, Fischer BS, Westhouse RA, Lee FY. Discovery of Clinical Candidate BMS-906024: A Potent Pan-Notch Inhibitor for the Treatment of Leukemia and Solid Tumors. ACS Med Chem Lett 2015; 6:523-7. [PMID: 26005526 DOI: 10.1021/acsmedchemlett.5b00001] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2015] [Accepted: 03/11/2015] [Indexed: 01/02/2023] Open
Abstract
Structure-activity relationships in a series of (2-oxo-1,4-benzodiazepin-3-yl)-succinamides identified highly potent inhibitors of γ-secretase mediated signaling of Notch1/2/3/4 receptors. On the basis of its robust in vivo efficacy at tolerated doses in Notch driven leukemia and solid tumor xenograft models, 12 (BMS-906024) was selected as a candidate for clinical evaluation.
Collapse
Affiliation(s)
- Ashvinikumar V. Gavai
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Claude Quesnelle
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Derek Norris
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Wen-Ching Han
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Patrice Gill
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Weifang Shan
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Aaron Balog
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Ke Chen
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - Andrew Tebben
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Richard Rampulla
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Dauh-Rurng Wu
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Yingru Zhang
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Arvind Mathur
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Ronald White
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Anne Rose
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Haiqing Wang
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Zheng Yang
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Asoka Ranasinghe
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Celia D’Arienzo
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Victor Guarino
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Lan Xiao
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Ching Su
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Gerry Everlof
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Vinod Arora
- Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - Ding Ren Shen
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Mary Ellen Cvijic
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Krista Menard
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Mei-Li Wen
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Jere Meredith
- Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - George Trainor
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Louis J. Lombardo
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Richard Olson
- Bristol-Myers Squibb Research and Development, 5 Research Parkway, Wallingford, Connecticut 06492, United States
| | - Phil S. Baran
- Department
of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037, United States
| | - John T. Hunt
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Gregory D. Vite
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Bruce S. Fischer
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Richard A. Westhouse
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Francis Y. Lee
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey 08543, United States
| |
Collapse
|
9
|
Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Liu Q, Batt D, Lombardo LJ, Vyas D, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Lippy J, Khan J, Sack JS, Purandare AV. 9H-Carbazole-1-carboxamides as potent and selective JAK2 inhibitors. Bioorg Med Chem Lett 2015; 25:2809-12. [PMID: 25987372 DOI: 10.1016/j.bmcl.2015.04.101] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2015] [Revised: 04/28/2015] [Accepted: 04/30/2015] [Indexed: 02/07/2023]
Abstract
The discovery, synthesis, and characterization of 9H-carbazole-1-carboxamides as potent and selective ATP-competitive inhibitors of Janus kinase 2 (JAK2) are discussed. Optimization for JAK family selectivity led to compounds 14 and 21, with greater than 45-fold selectivity for JAK2 over all other members of the JAK kinase family.
Collapse
Affiliation(s)
- Kurt Zimmermann
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA.
| | - Xiaopeng Sang
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA
| | - Harold A Mastalerz
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA
| | - Walter L Johnson
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA
| | - Guifen Zhang
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA
| | - Qingjie Liu
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Douglas Batt
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Louis J Lombardo
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Dinesh Vyas
- Bristol-Myers Squibb Co., 5 Research Parkway, Wallingford, CT 06492-1951, USA
| | - George L Trainor
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - John S Tokarski
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Matthew V Lorenzi
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Dan You
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Marco M Gottardis
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Jonathan Lippy
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Javed Khan
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - John S Sack
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| | - Ashok V Purandare
- Bristol-Myers Squibb Co., Province Line Rd., Princeton, NJ 08540-4000, USA
| |
Collapse
|
10
|
Kester RF, Donnell AF, Lou Y, Remiszewski SW, Lombardo LJ, Chen S, Le NT, Lo J, Moliterni JA, Han X, Hogg JH, Liang W, Michoud C, Rupert KC, Mischke S, Le K, Weisel M, Janson CA, Lukacs CM, Fretland AJ, Hong K, Polonskaia A, Gao L, Li S, Solis DS, Aguilar D, Tardell C, Dvorozniak M, Tannu S, Lee EC, Schutt AD, Goggin B. Optimization of benzodiazepinones as selective inhibitors of the X-linked inhibitor of apoptosis protein (XIAP) second baculovirus IAP repeat (BIR2) domain. J Med Chem 2013; 56:7788-803. [PMID: 24093940 DOI: 10.1021/jm400732v] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The IAPs are key regulators of the apoptotic pathways and are commonly overexpressed in many cancer cells. IAPs contain one to three BIR domains that are crucial for their inhibitory function. The pro-survival properties of XIAP come from binding of the BIR domains to the pro-apoptotic caspases. The BIR3 domain of XIAP binds and inhibits caspase 9, while the BIR2 domain binds and inhibits the terminal caspases 3 and 7. While XIAP BIR3 inhibitors have previously been reported, they also inhibit cIAP1/2 and promote the release of TNFα, potentially limiting their therapeutic utility. This paper will focus on the optimization of selective XIAP BIR2 inhibitors leading to the discovery of highly potent benzodiazepinone 36 (IC50 = 45 nM), which has high levels of selectivity over XIAP BIR3 and cIAP1 BIR2/3 and shows efficacy in a xenograft pharmacodynamic model monitoring caspase activity while not promoting the release of TNFα in vitro.
Collapse
Affiliation(s)
- Robert F Kester
- Departments of Discovery Chemistry, ‡Discovery Technologies, §Non-clinical Safety, Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc. , 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Donnell AF, Michoud C, Rupert KC, Han X, Aguilar D, Frank KB, Fretland AJ, Gao L, Goggin B, Hogg JH, Hong K, Janson CA, Kester RF, Kong N, Le K, Li S, Liang W, Lombardo LJ, Lou Y, Lukacs CM, Mischke S, Moliterni JA, Polonskaia A, Schutt AD, Solis DS, Specian A, Taylor RT, Weisel M, Remiszewski SW. Benzazepinones and Benzoxazepinones as Antagonists of Inhibitor of Apoptosis Proteins (IAPs) Selective for the Second Baculovirus IAP Repeat (BIR2) Domain. J Med Chem 2013; 56:7772-87. [DOI: 10.1021/jm400731m] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- Andrew F. Donnell
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Christophe Michoud
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Kenneth C. Rupert
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Xiaochun Han
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Douglas Aguilar
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Karl B. Frank
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Adrian J. Fretland
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Lin Gao
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Barry Goggin
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - J. Heather Hogg
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Kyoungja Hong
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Cheryl A. Janson
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Robert F. Kester
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Norman Kong
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Kang Le
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Shirley Li
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Weiling Liang
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Louis J. Lombardo
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Yan Lou
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Christine M. Lukacs
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Steven Mischke
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - John A. Moliterni
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Ann Polonskaia
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Andrew D. Schutt
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Dave S. Solis
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Anthony Specian
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Robert T. Taylor
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Martin Weisel
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| | - Stacy W. Remiszewski
- Departments of Discovery
Chemistry, ‡Discovery Technologies, §Non-clinical Safety,
Early ADME, and ∥Discovery Oncology, Hoffmann-La Roche Inc., 340 Kingsland Street, Nutley, New Jersey 07110, United States
| |
Collapse
|
12
|
Schroeder GM, Wei D, Banfi P, Cai ZW, Lippy J, Menichincheri M, Modugno M, Naglich J, Penhallow B, Perez HL, Sack J, Schmidt RJ, Tebben A, Yan C, Zhang L, Galvani A, Lombardo LJ, Borzilleri RM. Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists. Bioorg Med Chem Lett 2012; 22:3951-6. [PMID: 22608393 DOI: 10.1016/j.bmcl.2012.04.106] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2012] [Revised: 04/20/2012] [Accepted: 04/23/2012] [Indexed: 01/30/2023]
Abstract
5-Butyl-1,4-diphenyl pyrazole and 2-amino-5-chloro pyrimidine acylsulfonamides were developed as potent dual antagonists of Bcl-2 and Bcl-xL. Compounds were optimized for binding to the I88, L92, I95, and F99 pockets normally occupied by pro-apoptotic protein Bim. An X-ray crystal structure confirmed the proposed binding mode. Observation of cytochrome c release from isolated mitochondria in MV-411 cells provides further evidence of target inhibition. Compounds demonstrated submicromolar antiproliferative activity in Bcl-2/Bcl-xL dependent cell lines.
Collapse
|
13
|
Harikrishnan LS, Kamau MG, Wan H, Inghrim JA, Zimmermann K, Sang X, Mastalerz HA, Johnson WL, Zhang G, Lombardo LJ, Poss MA, Trainor GL, Tokarski JS, Lorenzi MV, You D, Gottardis MM, Baldwin KF, Lippy J, Nirschl DS, Qiu R, Miller AV, Khan J, Sack JS, Purandare AV. Pyrrolo[1,2-f]triazines as JAK2 inhibitors: achieving potency and selectivity for JAK2 over JAK3. Bioorg Med Chem Lett 2011; 21:1425-8. [PMID: 21282055 DOI: 10.1016/j.bmcl.2011.01.022] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2010] [Revised: 01/04/2011] [Accepted: 01/06/2011] [Indexed: 12/31/2022]
Abstract
SAR studies of pyrrolo[1,2-f]triazines as JAK2 inhibitors is presented. Achieving JAK2 inhibition selectively over JAK3 is discussed.
Collapse
|
14
|
Schroeder GM, An Y, Cai ZW, Chen XT, Clark C, Cornelius LAM, Dai J, Gullo-Brown J, Gupta A, Henley B, Hunt JT, Jeyaseelan R, Kamath A, Kim K, Lippy J, Lombardo LJ, Manne V, Oppenheimer S, Sack JS, Schmidt RJ, Shen G, Stefanski K, Tokarski JS, Trainor GL, Wautlet BS, Wei D, Williams DK, Zhang Y, Zhang Y, Fargnoli J, Borzilleri RM. Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily. J Med Chem 2010; 52:1251-4. [PMID: 19260711 DOI: 10.1021/jm801586s] [Citation(s) in RCA: 239] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors. Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aqueous solubility and kinase selectivity. Analogue 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration. Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclinical safety profiles, 10 has been advanced into phase I clinical trials.
Collapse
Affiliation(s)
- Gretchen M Schroeder
- Bristol-Myers Squibb Research and Development, Princeton, New Jersey, 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, Jeyaseelan R, Mortillo S, Wautlet BS, Krishnan B, Kukral D, Malone H, Lewin AC, Henley BJ, Fargnoli J. The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases. Mol Cancer Ther 2010; 9:369-78. [DOI: 10.1158/1535-7163.mct-09-0472] [Citation(s) in RCA: 61] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
|
16
|
Williams DK, Chen XT, Tarby C, Kaltenbach R, Cai ZW, Tokarski JS, An Y, Sack JS, Wautlet B, Gullo-Brown J, Henley BJ, Jeyaseelan R, Kellar K, Manne V, Trainor GL, Lombardo LJ, Fargnoli J, Borzilleri RM. Design, synthesis and structure-activity relationships of novel biarylamine-based Met kinase inhibitors. Bioorg Med Chem Lett 2010; 20:2998-3002. [PMID: 20382527 DOI: 10.1016/j.bmcl.2010.01.042] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2009] [Revised: 01/08/2010] [Accepted: 01/11/2010] [Indexed: 12/24/2022]
Abstract
Biarylamine-based inhibitors of Met kinase have been identified. Lead compounds demonstrate nanomolar potency in Met kinase biochemical assays and significant activity in the Met-driven GTL-16 human gastric carcinoma cell line. X-ray crystallography revealed that these compounds adopt a bioactive conformation, in the kinase domain, consistent with that previously seen with 2-pyridone-based Met kinase inhibitors. Compound 9b demonstrated potent in vivo antitumor activity in the GTL-16 human tumor xenograft model.
Collapse
Affiliation(s)
- David K Williams
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Johnson BM, Kamath AV, Leet JE, Liu X, Bhide RS, Tejwani RW, Zhang Y, Qian L, Wei DD, Lombardo LJ, Shu YZ. Metabolism of 5-Isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737): Identification of an UnusualN-Acetylglucosamine Conjugate in the Cynomolgus Monkey. Drug Metab Dispos 2008; 36:2475-83. [DOI: 10.1124/dmd.108.022624] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
18
|
Kim KS, Zhang L, Schmidt R, Cai ZW, Wei D, Williams DK, Lombardo LJ, Trainor GL, Xie D, Zhang Y, An Y, Sack JS, Tokarski JS, Darienzo C, Kamath A, Marathe P, Zhang Y, Lippy J, Jeyaseelan R, Wautlet B, Henley B, Gullo-Brown J, Manne V, Hunt JT, Fargnoli J, Borzilleri RM. Discovery of Pyrrolopyridine−Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities. J Med Chem 2008; 51:5330-41. [DOI: 10.1021/jm800476q] [Citation(s) in RCA: 109] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- Kyoung Soon Kim
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Liping Zhang
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Robert Schmidt
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Zhen-Wei Cai
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Donna Wei
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - David K. Williams
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Louis J. Lombardo
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - George L. Trainor
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Dianlin Xie
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Yaquan Zhang
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Yongmi An
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - John S. Sack
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - John S. Tokarski
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Celia Darienzo
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Amrita Kamath
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Punit Marathe
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Yueping Zhang
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Jonathan Lippy
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Robert Jeyaseelan
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Barri Wautlet
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Benjamin Henley
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Johnni Gullo-Brown
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Veeraswamy Manne
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - John T. Hunt
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Joseph Fargnoli
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| | - Robert M. Borzilleri
- Departments of Oncology Chemistry, Oncology Drug Discovery, Structural Biology and Modeling, and Metabolism and Pharmacokinetics, Bristol-Myers Squibb Pharmaceutical Research & Development, P.O. Box 4000, Princeton, New Jersey 08543-4000
| |
Collapse
|
19
|
Cai ZW, Wei D, Schroeder GM, Cornelius LA, Kim K, Chen XT, Schmidt RJ, Williams DK, Tokarski JS, An Y, Sack JS, Manne V, Kamath A, Zhang Y, Marathe P, Hunt JT, Lombardo LJ, Fargnoli J, Borzilleri RM. Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors. Bioorg Med Chem Lett 2008; 18:3224-9. [DOI: 10.1016/j.bmcl.2008.04.047] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2008] [Revised: 04/21/2008] [Accepted: 04/22/2008] [Indexed: 11/26/2022]
|
20
|
Ruel R, Thibeault C, L'Heureux A, Martel A, Cai ZW, Wei D, Qian L, Barrish JC, Mathur A, D'Arienzo C, Hunt JT, Kamath A, Marathe P, Zhang Y, Derbin G, Wautlet B, Mortillo S, Jeyaseelan R, Henley B, Tejwani R, Bhide RS, Trainor GL, Fargnoli J, Lombardo LJ. Discovery and preclinical studies of 5-isopropyl-6-(5-methyl-1,3,4-oxadiazol-2-yl)-N-(2-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine (BMS-645737), an in vivo active potent VEGFR-2 inhibitor. Bioorg Med Chem Lett 2008; 18:2985-9. [PMID: 18395443 DOI: 10.1016/j.bmcl.2008.03.057] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2008] [Revised: 03/18/2008] [Accepted: 03/18/2008] [Indexed: 10/22/2022]
Abstract
We report herein a series of substituted N-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amines as inhibitors of vascular endothelial growth factor receptor-2 tyrosine kinase. Through structure-activity relationship studies, biochemical potency, pharmacokinetics, and kinase selectivity were optimized to afford BMS-645737 (13), a compound with good preclinical in vivo activity against human tumor xenograft models.
Collapse
Affiliation(s)
- Réjean Ruel
- Bristol-Myers Squibb, Research and Development, Candiac, Que., Canada J5R 1J1.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Cai ZW, Zhang Y, Borzilleri RM, Qian L, Barbosa S, Wei D, Zheng X, Wu L, Fan J, Shi Z, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Kamath A, Marathe P, D'Arienzo C, Derbin G, Barrish JC, Robl JA, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Discovery of brivanib alaninate ((S)-((R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-yl)2-aminopropanoate), a novel prodrug of dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinase inhibitor (BMS-540215). J Med Chem 2008; 51:1976-80. [PMID: 18288793 DOI: 10.1021/jm7013309] [Citation(s) in RCA: 113] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
A series of amino acid ester prodrugs of the dual VEGFR-2/FGFR-1 kinase inhibitor 1 (BMS-540215) was prepared in an effort to improve the aqueous solubility and oral bioavailability of the parent compound. These prodrugs were evaluated for their ability to liberate parent drug 1 in in vitro and in vivo systems. The l-alanine prodrug 8 (also known as brivanib alaninate/BMS-582664) was selected as a development candidate and is presently in phase II clinical trials.
Collapse
Affiliation(s)
- Zhen-wei Cai
- Bristol-Myers Squibb Research and Development, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Bendale P, Olepu S, Suryadevara PK, Bulbule V, Rivas K, Nallan L, Smart B, Yokoyama K, Ankala S, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Buckner FS, Chakrabarti D, Verlinde CLMJ, Van Voorhis WC, Gelb MH. Second generation tetrahydroquinoline-based protein farnesyltransferase inhibitors as antimalarials. J Med Chem 2007; 50:4585-605. [PMID: 17722901 PMCID: PMC2894570 DOI: 10.1021/jm0703340] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Substituted tetrahydroquinolines (THQs) have been previously identified as inhibitors of mammalian protein farnesyltransferase (PFT). Previously we showed that blocking PFT in the malaria parasite led to cell death and that THQ-based inhibitors are the most potent among several structural classes of PFT inhibitors (PFTIs). We have prepared 266 THQ-based PFTIs and discovered several compounds that inhibit the malarial enzyme in the sub- to low-nanomolar range and that block the growth of the parasite (P. falciparum) in the low-nanomolar range. This body of structure-activity data can be rationalized in most cases by consideration of the X-ray structure of one of the THQs bound to mammalian PFT together with a homology structural model of the malarial enzyme. The results of this study provide the basis for selection of antimalarial PFTIs for further evaluation in preclinical drug discovery assays.
Collapse
Affiliation(s)
- Pravin Bendale
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Srinivas Olepu
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | | | - Vivek Bulbule
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Kasey Rivas
- Department of Medicine, University of Washington, Seattle, Washington 98195
- Department of Pathobiology, University of Washington, Seattle, Washington 98195
| | - Laxman Nallan
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Brian Smart
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Kohei Yokoyama
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Sudha Ankala
- Department of Chemistry, University of Washington, Seattle, Washington 98195
| | - Prakash Rao Pendyala
- Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida 32826
| | - David Floyd
- Pharmacopeia Drug Discovery, Princeton, New Jersey
| | - Louis J. Lombardo
- Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000
| | - David K. Williams
- Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000
| | - Frederick S. Buckner
- Department of Medicine, University of Washington, Seattle, Washington 98195
- Department of Pathobiology, University of Washington, Seattle, Washington 98195
| | - Debopam Chakrabarti
- Department of Molecular Biology and Microbiology, University of Central Florida, Orlando, Florida 32826
| | | | - Wesley C. Van Voorhis
- Department of Medicine, University of Washington, Seattle, Washington 98195
- Department of Pathobiology, University of Washington, Seattle, Washington 98195
| | - Michael H. Gelb
- Department of Chemistry, University of Washington, Seattle, Washington 98195
- Department of Biochemistry, University of Washington, Seattle, Washington 98195
- To whom correspondence should be addressed. Phone: 206-543-7142. Fax: 206-685-8665.
| |
Collapse
|
23
|
Van Voorhis WC, Rivas KL, Bendale P, Nallan L, Hornéy C, Barrett LK, Bauer KD, Smart BP, Ankala S, Hucke O, Verlinde CLMJ, Chakrabarti D, Strickland C, Yokoyama K, Buckner FS, Hamilton AD, Williams DK, Lombardo LJ, Floyd D, Gelb MH. Efficacy, pharmacokinetics, and metabolism of tetrahydroquinoline inhibitors of Plasmodium falciparum protein farnesyltransferase. Antimicrob Agents Chemother 2007; 51:3659-71. [PMID: 17606674 PMCID: PMC2043286 DOI: 10.1128/aac.00246-07] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
New antimalarials are urgently needed. We have shown that tetrahydroquinoline (THQ) protein farnesyltransferase (PFT) inhibitors (PFTIs) are effective against the Plasmodium falciparum PFT and are effective at killing P. falciparum in vitro. Previously described THQ PFTIs had limitations of poor oral bioavailability and rapid clearance from the circulation of rodents. In this paper, we validate both the Caco-2 cell permeability model for predicting THQ intestinal absorption and the in vitro liver microsome model for predicting THQ clearance in vivo. Incremental improvements in efficacy, oral absorption, and clearance rate were monitored by in vitro tests; and these tests were followed up with in vivo absorption, distribution, metabolism, and excretion studies. One compound, PB-93, achieved cure when it was given orally to P. berghei-infected rats every 8 h for a total of 72 h. However, PB-93 was rapidly cleared, and dosing every 12 h failed to cure the rats. Thus, the in vivo results corroborate the in vitro pharmacodynamics and demonstrate that 72 h of continuous high-level exposure to PFTIs is necessary to kill plasmodia. The metabolism of PB-93 was demonstrated by a novel technique that relied on double labeling with a radiolabel and heavy isotopes combined with radiometric liquid chromatography and mass spectrometry. The major liver microsome metabolite of PB-93 has the PFT Zn-binding N-methyl-imidazole removed; this metabolite is inactive in blocking PFT function. By solving the X-ray crystal structure of PB-93 bound to rat PFT, a model of PB-93 bound to malarial PFT was constructed. This model suggests areas of the THQ PFTIs that can be modified to retain efficacy and protect the Zn-binding N-methyl-imidazole from dealkylation.
Collapse
Affiliation(s)
- Wesley C Van Voorhis
- Department of Medicine, University of Washington, Room I-104-E, Health Sciences Building, Seattle, WA 98195-7185, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ. Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2. J Med Chem 2006; 49:3766-9. [PMID: 16789733 DOI: 10.1021/jm060347y] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Substituted 3-((2-(pyridin-2-ylamino)thiazol-5-ylmethyl)amino)benzamides were identified as potent and selective inhibitors of vascular endothelial growth factor receptor-2 (VEGFR-2) kinase activity. The enzyme kinetics associated with the VEGFR-2 inhibition of 14 (Ki=49+/-9 nM) confirmed that the aminothiazole-based analogues are competitive with ATP. Analogue 14 demonstrated excellent kinase selectivity, favorable pharmacokinetic properties in multiple species, and robust in vivo efficacy in human lung and colon carcinoma xenograft models.
Collapse
Affiliation(s)
- Robert M Borzilleri
- Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Tokarski JS, Newitt JA, Chang CYJ, Cheng JD, Wittekind M, Kiefer SE, Kish K, Lee FYF, Borzillerri R, Lombardo LJ, Xie D, Zhang Y, Klei HE. The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res 2006; 66:5790-7. [PMID: 16740718 DOI: 10.1158/0008-5472.can-05-4187] [Citation(s) in RCA: 477] [Impact Index Per Article: 26.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Chronic myeloid leukemia (CML) is caused by the constitutively activated tyrosine kinase breakpoint cluster (BCR)-ABL. Current frontline therapy for CML is imatinib, an inhibitor of BCR-ABL. Although imatinib has a high rate of clinical success in early phase CML, treatment resistance is problematic, particularly in later stages of the disease, and is frequently mediated by mutations in BCR-ABL. Dasatinib (BMS-354825) is a multitargeted tyrosine kinase inhibitor that targets oncogenic pathways and is a more potent inhibitor than imatinib against wild-type BCR-ABL. It has also shown preclinical activity against all but one of the imatinib-resistant BCR-ABL mutants tested to date. Analysis of the crystal structure of dasatinib-bound ABL kinase suggests that the increased binding affinity of dasatinib over imatinib is at least partially due to its ability to recognize multiple states of BCR-ABL. The structure also provides an explanation for the activity of dasatinib against imatinib-resistant BCR-ABL mutants.
Collapse
Affiliation(s)
- John S Tokarski
- Bristol-Myers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Kim KS, Lu S, Cornelius LA, Lombardo LJ, Borzilleri RM, Schroeder GM, Sheng C, Rovnyak G, Crews D, Schmidt RJ, Williams DK, Bhide RS, Traeger SC, McDonnell PA, Mueller L, Sheriff S, Newitt JA, Pudzianowski AT, Yang Z, Wild R, Lee FY, Batorsky R, Ryder JS, Ortega-Nanos M, Shen H, Gottardis M, Roussell DL. Synthesis and SAR of pyrrolotriazine-4-one based Eg5 inhibitors. Bioorg Med Chem Lett 2006; 16:3937-42. [PMID: 16730979 DOI: 10.1016/j.bmcl.2006.05.037] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2006] [Revised: 05/08/2006] [Accepted: 05/08/2006] [Indexed: 11/20/2022]
Abstract
Synthesis and SAR of substituted pyrrolotriazine-4-one analogues as Eg5 inhibitors are described. Many of these analogues displayed potent inhibitory activities in the Eg5 ATPase and A2780 cell proliferation assays. In addition, pyrrolotriazine-4-one analogue 26 demonstrated in vivo efficacy in an iv P388 murine leukemia model. Both NMR and X-ray crystallographic studies revealed that these analogues bind to an allosteric site on the Eg5 protein.
Collapse
Affiliation(s)
- Kyoung Soon Kim
- Department of Drug Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Bhide RS, Cai ZW, Zhang YZ, Qian L, Wei D, Barbosa S, Lombardo LJ, Borzilleri RM, Zheng X, Wu LI, Barrish JC, Kim SH, Leavitt K, Mathur A, Leith L, Chao S, Wautlet B, Mortillo S, Jeyaseelan R, Kukral D, Hunt JT, Kamath A, Fura A, Vyas V, Marathe P, D'Arienzo C, Derbin G, Fargnoli J. Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. J Med Chem 2006; 49:2143-6. [PMID: 16570908 DOI: 10.1021/jm051106d] [Citation(s) in RCA: 107] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
A series of substituted 4-(4-fluoro-1H-indol-5-yloxy)pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of vascular endothelial growth factor receptor-2 kinase is reported. Structure-activity relationship studies revealed that a methyl group at the 5-position and a substituted alkoxy group at the 6-position of the pyrrolo[2,1-f][1,2,4]triazine core gave potent compounds. Biochemical potency, kinase selectivity, and pharmacokinetics of the series were optimized and in vitro safety liabilities were minimized to afford BMS-540215 (12), which demonstrated robust preclinical in vivo activity in human tumor xenograft models. The l-alanine prodrug of 12, BMS-582664 (21), is currently under evaluation in clinical trials for the treatment of solid tumors.
Collapse
Affiliation(s)
- Rajeev S Bhide
- Bristol-Myers Squibb, Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Tarby CM, Kaltenbach RF, Huynh T, Pudzianowski A, Shen H, Ortega-Nanos M, Sheriff S, Newitt JA, McDonnell PA, Burford N, Fairchild CR, Vaccaro W, Chen Z, Borzilleri RM, Naglich J, Lombardo LJ, Gottardis M, Trainor GL, Roussell DL. Inhibitors of human mitotic kinesin Eg5: Characterization of the 4-phenyl-tetrahydroisoquinoline lead series. Bioorg Med Chem Lett 2006; 16:2095-100. [PMID: 16458511 DOI: 10.1016/j.bmcl.2006.01.056] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2005] [Revised: 01/13/2006] [Accepted: 01/17/2006] [Indexed: 11/20/2022]
Abstract
In a high-throughput screening effort, a series of tetrahydroisoquinolines was identified as modest inhibitors of human Eg5. A medicinal chemistry optimization effort led to the identification of R-4-(3-hydroxyphenyl)-N,N-7,8-tetramethyl-3,4-dihydroisoquinoline-2(1H)-carboxamide (32a) as a potent inhibitor of human Eg5 (ATPase IC50 104 nM) with good anti-proliferative activity in A2780 cells (IC50 234 nM).
Collapse
Affiliation(s)
- Christine M Tarby
- Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, NJ 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS. Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors. J Med Chem 2005; 48:3991-4008. [PMID: 15943473 DOI: 10.1021/jm0501275] [Citation(s) in RCA: 56] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
A series of substituted 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines was identified as potent and selective inhibitors of the tyrosine kinase activity of the growth factor receptors VEGFR-2 (Flk-1, KDR) and FGFR-1. The enzyme kinetics associated with the VEGFR-2 inhibition of compound 50 (K(i) = 52 +/- 3 nM) confirmed that the pyrrolo[2,1-f][1,2,4]triazine analogues are competitive with ATP. Several analogues demonstrated low-nanomolar inhibition of VEGF- and FGF-dependent human umbilical vein endothelial cell (HUVEC) proliferation. Replacement of the C6-ester substituent of the pyrrolo[2,1-f][1,2,4]triazine core with heterocyclic bioisosteres, such as substituted 1,3,5-oxadiazoles, afforded compounds with excellent oral bioavailability in mice (i.e., 50 F(po) = 79%). Significant antitumor efficacy was observed with compounds 44, 49, and 50 against established L2987 human lung carcinoma xenografts implanted in athymic mice. A full account of the synthesis, structure-activity relationships, pharmacology, and pharmacokinetic properties of analogues within the series is presented.
Collapse
MESH Headings
- Administration, Oral
- Animals
- Antineoplastic Agents/chemical synthesis
- Antineoplastic Agents/chemistry
- Antineoplastic Agents/pharmacology
- Biological Availability
- Blood Proteins/metabolism
- Cell Proliferation/drug effects
- Drug Design
- Endothelium, Vascular/cytology
- Humans
- Hydroxamic Acids/chemical synthesis
- Hydroxamic Acids/chemistry
- Hydroxamic Acids/pharmacology
- In Vitro Techniques
- Male
- Mice
- Mice, Inbred BALB C
- Mice, Nude
- Microsomes, Liver/metabolism
- Models, Molecular
- Oxadiazoles/chemical synthesis
- Oxadiazoles/chemistry
- Oxadiazoles/pharmacology
- Protein Binding
- Pyrroles/chemical synthesis
- Pyrroles/chemistry
- Pyrroles/pharmacology
- Receptor Protein-Tyrosine Kinases/antagonists & inhibitors
- Receptor Protein-Tyrosine Kinases/chemistry
- Receptor, Fibroblast Growth Factor, Type 1
- Receptors, Fibroblast Growth Factor/antagonists & inhibitors
- Receptors, Fibroblast Growth Factor/chemistry
- Structure-Activity Relationship
- Triazines/chemical synthesis
- Triazines/chemistry
- Triazines/pharmacology
- Vascular Endothelial Growth Factor Receptor-2/antagonists & inhibitors
- Vascular Endothelial Growth Factor Receptor-2/chemistry
- Xenograft Model Antitumor Assays
Collapse
Affiliation(s)
- Robert M Borzilleri
- Department of Oncology Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Hornéy CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, Chakrabarti D, Gelb MH, Van Voorhis WC. Protein Farnesyltransferase Inhibitors Exhibit Potent Antimalarial Activity. J Med Chem 2005; 48:3704-13. [PMID: 15916422 DOI: 10.1021/jm0491039] [Citation(s) in RCA: 132] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
New therapeutics to combat malaria are desperately needed. Here we show that the enzyme protein farnesyltransferase (PFT) from the malaria parasite Plasmodium falciparum (P. falciparum) is an ideal drug target. PFT inhibitors (PFTIs) are well tolerated in man, but are highly cytotoxic to P. falciparum. Because of their anticancer properties, PFTIs comprise a highly developed class of compounds. PFTIs are ideal for the rapid development of antimalarials, allowing "piggy-backing" on previously garnered information. Low nanomolar concentrations of tetrahydroquinoline (THQ)-based PFTIs inhibit P. falciparum PFT and are cytotoxic to cultured parasites. Biochemical studies suggest inhibition of parasite PFT as the mode of THQ cytotoxicity. Studies with malaria-infected mice show that THQ PFTIs dramatically reduce parasitemia and lead to parasite eradication in the majority of animals. These studies validate P. falciparum PFT as a target for the development of antimalarials and describe a potent new class of THQ PFTIs with antimalaria activity.
Collapse
Affiliation(s)
- Laxman Nallan
- Department of Chemistry, University of Washington, Seattle, Washington 98195, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
31
|
Lombardo LJ, Camuso A, Clark J, Fager K, Gullo-Brown J, Hunt JT, Inigo I, Kan D, Koplowitz B, Lee F, McGlinchey K, Qian L, Ricca C, Rovnyak G, Traeger S, Tokarski J, Williams DK, Wu LI, Zhao Y, Manne V, Bhide RS. Design, synthesis, and structure–activity relationships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg Med Chem Lett 2005; 15:1895-9. [PMID: 15780629 DOI: 10.1016/j.bmcl.2005.02.004] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2005] [Revised: 01/31/2005] [Accepted: 02/01/2005] [Indexed: 10/25/2022]
Abstract
Tetrahydroquinoline-based small molecule inhibitors of farnesyltransferase (FT) have been identified. Lead compounds were shown to have nanomolar to sub-nanomolar activity in biochemical assays with excellent potency in a Ras-mutated cellular reversion assay. BMS-316810 (9e), a 0.7 nM FT inhibitor, was orally-active in a nude mouse tumor allograft efficacy study.
Collapse
Affiliation(s)
- Louis J Lombardo
- Bristol-Myers Squibb Pharmaceutical Research Institute, PO Box 4000, Princeton, NJ 08543-4000, United States.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Huryn DM, Konradi AW, Ashwell S, Freedman SB, Lombardo LJ, Pleiss MA, Thorsett ED, Yednock T, Kennedy JD. The identification and optimization of orally efficacious, small molecule VLA-4 antagonists. Curr Top Med Chem 2005; 4:1473-84. [PMID: 15544538 DOI: 10.2174/1568026043387467] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The identification of orally active, small molecule antagonists of the alpha4beta1 integrin, VLA-4, could lead to therapeutic agents with utility in a number of clinical settings, including asthma, multiple sclerosis and IBD. Starting from CDR3 sequences conserved among neutralizing alpha4 antibodies, peptides were identified that antagonized VLA-4 mediated adhesion in vitro. Through a series of structural modifications, these peptides evolved into small molecules that exhibited high potency and selectivity for VLA-4 in cell adhesion assays. Finally, through the optimization of physical and pharmacokinetic properties, compounds were identified that exhibited oral activity in animal models of asthma and multiple sclerosis.
Collapse
|
33
|
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2005; 47:6658-61. [PMID: 15615512 DOI: 10.1021/jm049486a] [Citation(s) in RCA: 979] [Impact Index Per Article: 51.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.
Collapse
Affiliation(s)
- Louis J Lombardo
- Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
34
|
Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004; 47:6658-6661. [PMID: 15615512 DOI: 10.1021/jm049486a/suppl_file/jm049486asi20041105_112036.pdf] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
A series of substituted 2-(aminopyridyl)- and 2-(aminopyrimidinyl)thiazole-5-carboxamides was identified as potent Src/Abl kinase inhibitors with excellent antiproliferative activity against hematological and solid tumor cell lines. Compound 13 was orally active in a K562 xenograft model of chronic myelogenous leukemia (CML), demonstrating complete tumor regressions and low toxicity at multiple dose levels. On the basis of its robust in vivo activity and favorable pharmacokinetic profile, 13 was selected for additional characterization for oncology indications.
Collapse
Affiliation(s)
- Louis J Lombardo
- Bristol-Myers Squibb Pharmaceutical Research Institute, P.O. Box 4000, Princeton, New Jersey 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Manne V, Lee FYF, Bol DK, Gullo-Brown J, Fairchild CR, Lombardo LJ, Smykla RA, Vite GD, Wen MLD, Yu C, Wong TW, Hunt JT. Apoptotic and Cytostatic Farnesyltransferase Inhibitors Have Distinct Pharmacology and Efficacy Profiles in Tumor Models. Cancer Res 2004; 64:3974-80. [PMID: 15173010 DOI: 10.1158/0008-5472.can-03-3849] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BMS-214662 and BMS-225975 are tetrahydrobenzodiazepine-based farnesyltransferase inhibitors (FTIs) that have nearly identical structures and very similar pharmacological profiles associated with farnesyltransferase (FT) inhibition. Despite their similar activity against FT in vitro and in cells, these compounds differ dramatically in their apoptotic potency and tumor-regressing activity in vivo. BMS-214662 is the most potent apoptotic FTI known and exhibits curative responses in mice bearing a variety of staged human tumor xenografts such as HCT-116 human colon tumor. By contrast, BMS-225975 does not cause tumor regression and at best causes partial tumor growth inhibition in staged HCT-116 human colon tumor xenografts. Lack of tumor regression activity in BMS-225975 was attributable to its relatively weak apoptotic potency, not to poor cell permeability or pharmacokinetics. Both compounds were equally effective in inhibiting Ras processing and causing accumulation of a variety of nonfarnesylated substrates of FT in HCT-116 cells. Because BMS-225975 has poor apoptotic activity compared with BMS-214662 but inhibits FT to the same extent as BMS-214662, it is very unlikely that FT inhibition alone can account for the apoptotic potency of BMS-214662. Clearly distinct patterns of sensitivities in a cell line panel were obtained for the apoptotic FTI BMS-214662 and the cytostatic FTI BMS-225975. Activation of the c-Jun-NH(2)-terminal kinase pathway was readily observed with BMS-214662 but not with BMS-225975. We developed a highly sensitive San-1 murine xenograft tumor model that is particularly useful for evaluating the in vivo activity of cytostatic FTIs such as BMS-225975.
Collapse
Affiliation(s)
- Veeraswamy Manne
- Oncology Drug Discovery and Discovery Chemistry, Bristol-Myers Squibb Company Pharmaceutical Research Institute, Princeton, New Jersey 08543, USA.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Haut MW, Leach S, Kuwabara H, Whyte S, Callahan T, Ducatman A, Lombardo LJ, Gupta N. Verbal working memory and solvent exposure: a positron emission tomography study. Neuropsychology 2001. [PMID: 11055257 DOI: 10.1037//0894-4105.14.4.551] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022] Open
Abstract
Neuropsychological studies have documented frontal dysfunction in patients with a history of exposure to organic solvents. The deficits typically observed in these patients appear to be related to working memory (WM). This study used [15O] water positron emission tomography (PET) to examine the pattern of neural activation during verbal working memory in patients with a history of exposure to solvents. Six individuals with solvent exposure were compared with 6 age- and education-matched controls. On the 2 WM tasks examined with PET, with equivalent task performance, participants with solvent exposure demonstrated frontal peaks that were atypical for the tasks, whereas the posterior peaks were typical for the tasks. The results support frontal dysfunction and compensatory use within anterior regions of the WM system in patients with solvent exposure.
Collapse
Affiliation(s)
- M W Haut
- Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown 26506, USA.
| | | | | | | | | | | | | | | |
Collapse
|
37
|
Haut MW, Leach S, Kuwabara H, Whyte S, Callahan T, Ducatman A, Lombardo LJ, Gupta N. Verbal working memory and solvent exposure: a positron emission tomography study. Neuropsychology 2000; 14:551-8. [PMID: 11055257 DOI: 10.1037/0894-4105.14.4.551] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Neuropsychological studies have documented frontal dysfunction in patients with a history of exposure to organic solvents. The deficits typically observed in these patients appear to be related to working memory (WM). This study used [15O] water positron emission tomography (PET) to examine the pattern of neural activation during verbal working memory in patients with a history of exposure to solvents. Six individuals with solvent exposure were compared with 6 age- and education-matched controls. On the 2 WM tasks examined with PET, with equivalent task performance, participants with solvent exposure demonstrated frontal peaks that were atypical for the tasks, whereas the posterior peaks were typical for the tasks. The results support frontal dysfunction and compensatory use within anterior regions of the WM system in patients with solvent exposure.
Collapse
Affiliation(s)
- M W Haut
- Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Morgantown 26506, USA.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Abstract
Occupational asthma is the most common form of occupational lung disease in the developed world at the present time. In this review, the epidemiology, pathogenesis/mechanisms, clinical presentations, management, and prevention of occupational asthma are discussed. The population attributable risk of asthma due to occupational exposures is considerable. Current understanding of the mechanisms by which many agents cause occupational asthma is limited, especially for low-molecular-weight sensitizers and irritants. The diagnosis of occupational asthma is generally established on the basis of a suggestive history of a temporal association between exposure and the onset of symptoms and objective evidence that these symptoms are related to airflow limitation. Early diagnosis, elimination of exposure to the responsible agent, and early use of inhaled steroids may play important roles in the prevention of long-term persistence of asthma. Persistent occupational asthma is often associated with substantial disability and consequent impacts on income and quality of life. Prevention of new cases is the best approach to reducing the burden of asthma attributable to occupational exposures. Future research needs are identified.
Collapse
Affiliation(s)
- L J Lombardo
- Division of Occupational and Environmental Medicine, University of California, San Francisco, California 94143-0843, USA
| | | |
Collapse
|
39
|
Lombardo LJ. Phosphodiesterase-IV Inhibitors: Novel Therapeutics for the Treatment of Inflammatory Diseases. Curr Pharm Des 1995. [DOI: 10.2174/1381612801666220917224109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The identification and characterization of the multiple isoforms of the phosphodiesterase enzyme has generated considerable interest in the preparation of selective inhibitors of these isozymes. Phosphodiesterase-IV (PDE-IV) is a cyclic AMP-specific phosphodiesterase which has been shown to play an important role in the regulation of inflammatory and immune cell activation. Thus, it has been proposed that selective PDE-IV inhibitors may be useful for the treatment of inflammatory diseases.
A diversity of structural types have been reported as selective PDE-IV inhibitors. Molecular modeling studies have played an important role in the discovery of these agents. An analysis of the structure-activity relationships (SAR) of novel inhibitors and their associated in vitro
and in vivo profiles will be discussed.
Collapse
|
40
|
Howell RE, Woeppel SL, Howell DE, Rubin EB, Jenkins LP, Golankiewicz JM, Lombardo LJ, Heaslip RJ. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Inflamm Res 1995; 44 Suppl 2:S172-3. [PMID: 8548383 DOI: 10.1007/bf01778317] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023] Open
Affiliation(s)
- R E Howell
- Wyeth-Ayerst Research, Princeton, NJ 08543-8000, USA
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Heaslip RJ, Lombardo LJ, Golankiewicz JM, Ilsemann BA, Evans DY, Sickels BD, Mudrick JK, Bagli J, Weichman BM. Phosphodiesterase-IV inhibition, respiratory muscle relaxation and bronchodilation by WAY-PDA-641. J Pharmacol Exp Ther 1994; 268:888-96. [PMID: 8114002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
The ability of 1-[3-(cyclopentyloxy)-4-methoxyphenyl]ethanone (E)-O-(aminocarbonyl) oxime) (WAY-PDA-641) to inhibit cyclic AMP-metabolizing phosphodiesterases (PDEs) and to relax respiratory muscle was explored as part of a program to identify a PDE-IV inhibitor for potential use in the treatment of asthma. WAY-PDA-641 was identified as a preferential inhibitor of PDE-IV, possessing 36 times greater potency versus canine trachealis PDE-IV than PDE-III (IC50, 4.2 x 10(-7) M and 1.5 x 10(-5) M, respectively). The classification of WAY-PDA-641 as a preferential PDE-IV inhibitor was supported in radioligand binding studies, which demonstrated that 10 microM WAY-PDA-641 did not displace ligands from a large number of receptors, and in functional studies, which used isolated guinea pig tracheal rings. Under conditions in which tracheal rings were made sensitive to the relaxant effects of PDE-IV or PDE-III inhibitors, WAY-PDA-641 induced relaxation with IC50S of 2.6 x 10(-8) M (PDE-IV) and 3.2 x 10(-5) M (PDE-III). Moreover, PDE-IV inhibitory concentrations of WAY-PDA-641 significantly potentiated the relaxant effects of albuterol. WAY-PDA-641 reversed tracheal contractions induced by prostaglandin F2 alpha, leukotriene D4 or histamine in a biphasic manner consistent with its activity as a preferential PDE-IV inhibitor. The IC50S for reversal of each spasmogen were similar, which confirmed that WAY-PDA-641 is a functional antagonist of respiratory muscle contraction.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- R J Heaslip
- Division of Inflammation/Bone Metabolism, Wyeth-Ayerst Research, Princeton, New Jersey
| | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Ellingboe JW, Lombardo LJ, Alessi TR, Nguyen TT, Guzzo F, Guinosso CJ, Bullington J, Browne EN, Bagli JF, Wrenn J. Antihyperglycemic activity of novel naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides. J Med Chem 1993; 36:2485-93. [PMID: 8355249 DOI: 10.1021/jm00069a006] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
A series of naphthalenyl 3H-1,2,3,5-oxathiadiazole 2-oxides was prepared and tested for antihyperglycemic activity in the db/db mouse, a model for type 2 (non-insulin dependent) diabetes mellitus. Substitution at the 1-, 5-, or 8-positions of the naphthalene ring with a halogen was found to be beneficial to antihyperglycemic activity. 4-[(5-Chloronaphthalen-2-yl)methyl]-3H-1,2,3,5-oxathiadiazole++ + 2-oxide (45), one of the most potent compounds in this series, was selected for further pharmacological evaluation.
Collapse
Affiliation(s)
- J W Ellingboe
- Division of Exploratory Chemistry, Wyeth-Ayerst Research, Princeton, New Jersey 08543-8000
| | | | | | | | | | | | | | | | | | | |
Collapse
|